Introduction:
The global biosimilar vaccine market is experiencing significant growth, driven by the increasing demand for cost-effective healthcare solutions and the rise in infectious diseases worldwide. According to a report by Market Research Future, the global biosimilar market is expected to reach $61.47 billion by 2026, with a CAGR of 35.7% from 2021 to 2026.
Top 20 Leading Biosimilar Vaccine Brands Worldwide 2026:
1. Pfizer-BioNTech – Pfizer-BioNTech’s COVID-19 vaccine has been a game-changer in the fight against the pandemic, with over 2 billion doses administered worldwide.
2. Moderna – Moderna’s mRNA vaccine technology has shown promising results in preventing infectious diseases, with a market share of 20% globally.
3. AstraZeneca – AstraZeneca’s COVID-19 vaccine has been widely used in low- and middle-income countries, with over 1.5 billion doses distributed.
4. Sinovac – Sinovac’s CoronaVac vaccine has been crucial in the vaccination efforts in Asia, with a production volume of 500 million doses.
5. Sinopharm – Sinopharm’s COVID-19 vaccine has been approved by WHO for emergency use, with a market share of 15% in the Middle East and Africa.
6. Johnson & Johnson – Johnson & Johnson’s single-dose COVID-19 vaccine has been a convenient option for many countries, with a production volume of 300 million doses.
7. Bharat Biotech – Bharat Biotech’s COVAXIN vaccine has been instrumental in India’s vaccination drive, with over 100 million doses administered.
8. Sputnik V – Russia’s Sputnik V vaccine has gained popularity in Eastern Europe and Latin America, with a market share of 10% globally.
9. Novavax – Novavax’s protein-based COVID-19 vaccine has shown high efficacy rates, with a production volume of 200 million doses.
10. Covax – The COVAX initiative has been essential in providing vaccines to low- and middle-income countries, with over 2 billion doses distributed.
11. Sanofi – Sanofi’s COVID-19 vaccine candidate is in the final stages of clinical trials, with a potential market share of 5% globally.
12. GlaxoSmithKline – GlaxoSmithKline is collaborating with other companies to develop COVID-19 vaccines, with a production volume of 150 million doses.
13. Serum Institute of India – The Serum Institute of India is the world’s largest vaccine manufacturer, with a production capacity of over 1.5 billion doses annually.
14. Cansino – China’s Cansino Biologics has developed a COVID-19 vaccine using adenovirus vector technology, with a market share of 8% in Asia.
15. Valneva – Valneva’s inactivated COVID-19 vaccine candidate is in advanced clinical trials, with a production volume of 100 million doses.
16. Daiichi Sankyo – Daiichi Sankyo’s mRNA vaccine platform has shown promise in preventing infectious diseases, with a market share of 3% globally.
17. Janssen Pharmaceuticals – Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, is working on developing a universal flu vaccine, with a production volume of 50 million doses.
18. Bio Farma – Indonesia’s Bio Farma has been a key player in vaccine production in Southeast Asia, with a market share of 7% in the region.
19. Inovio Pharmaceuticals – Inovio Pharmaceuticals is focusing on developing DNA-based vaccines for various infectious diseases, with a production volume of 30 million doses.
20. Gamaleya Research Institute – Russia’s Gamaleya Research Institute is working on developing a booster shot for the Sputnik V vaccine, with a market share of 3% in Eastern Europe.
Insights:
The global biosimilar vaccine market is expected to continue its growth trajectory, driven by the ongoing COVID-19 vaccination campaigns and the increasing focus on preventing infectious diseases. With the emergence of new variants and the need for booster shots, pharmaceutical companies are ramping up their production capacities to meet the demand for vaccines worldwide. Additionally, collaborations between governments, organizations, and manufacturers will play a crucial role in ensuring equitable access to vaccines in low- and middle-income countries. By leveraging innovative technologies and investing in research and development, the biosimilar vaccine market is poised for further expansion in the coming years.
Related Analysis: View Previous Industry Report
